Introduction
============

It has been increasingly acknowledged that environmental conditions during *in utero* development and early life may contribute to later onset health and disease. Evolving evidence suggests that paternal line exposures can also affect offspring health ([@dvz023-B1]). In particular, recent epidemiological reports have demonstrated that fathers' smoking is associated with an increased asthma risk and adiposity ([@dvz023-B7], [@dvz023-B8]) in their children.

Efforts in identifying biochemical mechanisms underlying such altered phenotypes have suggested epigenetic regulatory systems as a possible mechanistic link between environmental exposures and disease risk ([@dvz023-B9]). Epigenetic processes propagate regulatory information through mitosis essential for normal cell tissue function and development ([@dvz023-B10]). However, the epigenome also displays a high degree of structural adaption, and is determined by the combined response to both environmental and genetic factors ([@dvz023-B11]). The plasticity of these systems is important as they affect gene transcriptional activity and lead to long-lasting phenotypic changes in a disease-related manner that may also persist through meiosis, i.e. between generations.

There is clear evidence for altered epigenetic programming in response to tobacco smoke exposure, and several genome-wide studies have identified associations between personal smoking and changes in DNA methylation at single cytosine-phosphate-guanine (CpG) sites in whole blood or isolated peripheral blood mononuclear cells ([@dvz023-B12]). Methylation differences in cord blood of offspring born to smoking mothers have also been reported ([@dvz023-B16]), and such differences have been shown to persist until adulthood ([@dvz023-B19], [@dvz023-B20]). However, to our knowledge, evidence for a persistent methylation effect in offspring due to paternal tobacco use has yet to be demonstrated.

As DNA methylation can be stably propagated through mitotic and possibly meiotic cell divisions ([@dvz023-B10], [@dvz023-B11]), it seems theoretically plausible that offspring DNA methylation might be persistently influenced by paternal smoking exposure. We hereby present a hypothesis-generating analysis of a relatively small number of persons, with the aim to investigate the association between paternal smoking and genomic methylation patterns in offspring, and to explore potential biological impact of methylated regions and annotated genes.

Results
=======

Characteristics of the study populations are presented in [Table 1](#dvz023-T1){ref-type="table"}. There was an equal gender distribution in both cohorts, with mean age of 26 and 44 years for RHINESSA and European Community Respiratory Health Survey (ECRHS), respectively. A substantial proportion of the subjects had fathers that smoked during their childhood (66%), for RHINESSA participants this was due to enrichment of samples from persons with smoking fathers for DNA methylation.

###### 

characteristics of study participants by cohort, RHINESSA (*n* = 95), and ECRHS2 (*n* = 100)

  Descriptive variables                                                       RHINESSA    ECRHS       *P*-value[^a^](#tblfn1){ref-type="table-fn"}
  --------------------------------------------------------------------------- ----------- ----------- ----------------------------------------------
  Sex, *n* (%)                                                                                        
   Male                                                                       46 (48)     44 (44)     0.63
   Female                                                                     49 (52)     56 (56)     
  Age, mean ± SD                                                              26 ± 7.5    44 ± 6.2    \<0.001
  Range                                                                       11--45      31--54      
  Education, *n* (%)                                                                                  
   Primary                                                                    5 (5)       10 (10)     0.52
   Secondary                                                                  33 (35)     37 (37)     
   College/university                                                         51 (54)     53 (53)     
  Smoke status, *n* (%)                                                                               
   Never                                                                      68 (72)     41 (41)     \<0.001
   Ex                                                                         13 (14)     29 (29)     
   Current                                                                    14 (15)     30 (30)     
  Pack years, median (range)                                                  2 (0--23)   8 (1--37)   \<0.001
  Childhood smoke exposure, *n* (%)                                                                   
   Father smoked[^b^](#tblfn2){ref-type="table-fn"}                           66 (69)     63 (63)     0.67
   Mother smoked                                                              31 (33)     31 (31)     0.56
   Father and mother smoked                                                   31 (33)     24 (24)     0.44
   No parent smoked                                                           25 (26)     28 (28)     0.44
  Father education, *n* (%)[^c^](#tblfn3){ref-type="table-fn"}                                        
   Primary                                                                    10 (11)     46 (46)     \<0.001
   Secondary                                                                  38 (40)     22 (22)     
   College/university                                                         45 (47)     25 (25)     
  Mother education, *n* (%)[^c^](#tblfn3){ref-type="table-fn"}                                        
   Primary                                                                    11 (12)     62 (62)     
   Secondary                                                                  30 (32)     24 (24)     
   College/university                                                         43 (45)     7 (7)       
  Father age, childbirth, mean ±SD[^d^](#tblfn4){ref-type="table-fn"} range   31 ± 5.8    32 ± 6.5    0.69
                                                                              20--54      20--58      

^a^Chi square test for categorical variables; *t*-test for continuous (norm. distributed); Wald test for continuous (non-norm. distributed).

^b^RHINESSA sample included 23 persons with father smoking starting \<age 15 years, 43 with father smoking starting \>15 years and smoking for at least 4 years before conception of offspring, and 29 with non-smoking fathers/mothers.

^c^Missing RHINESSA; Educ. 6 (6%); father educ. 2 (2%); mother educ. 6 (6%); ECRHS; father educ./mother educ. 7 (7%).

^d^Father's age in ECRHS obtained from registry data.

Differentially Methylated Region Analysis
-----------------------------------------

Analysis of differentially methylated regions (DMRs) using comb-p identified six significant DMRs (Sidak-corrected *P* values: 0.0006--0.0173) ([Table 2](#dvz023-T2){ref-type="table"}). Among these DMRs, spanning between 3 and 5 DNA methylation sites, five were mapped to known genes. Two of the annotated genes were related to innate immune system pathways (*ATP6V1E1*, *C2*), whereas one DMR was involved in lipid metabolism regulation and fatty acid biosynthesis (*ACSF3*). One DMR overlapped with the catenin alpha 2 gene (*CTNNA2*), which are related to development of the nervous system. One DMR mapped to the WD repeat domain 60 gene (*WDR6*0), which regulates a variety of cellular processes including cell cycle progression, signal transduction, and gene regulation ([Table 3](#dvz023-T3){ref-type="table"}).

###### 

statistically significant DMRs (Sidak *P* \< 0.05) as associated with father's smoking

  Location                   No. probes   Slk[^a^](#tblfn5){ref-type="table-fn"}*P*-value   Sidak[^a^](#tblfn5){ref-type="table-fn"}*P*-value   Ref gene name and feature                          CpG feature
  -------------------------- ------------ ------------------------------------------------- --------------------------------------------------- -------------------------------------------------- -------------
  Chr22:18111277-18111521    4            6.01E-07                                          0.0019                                              ATP6V1E1 Intron, 5′UTR, cds                        Island
  Chr6:31865522-31865866     5            2.49E-06                                          0.0055                                              C2 TSS, intron, exon, 5′UTR                        Shore
  Chr2:80752765-80752967     4            1.69E-06                                          0.0006                                              CTNNA2 intron                                      NA
  Chr16:89180587-89180843    3            5.83E-06                                          0.0173                                              ACSF3 intron, cds, nc_intron, nc_exon, nc_intron   NA
  Chr1:182669050-182669315   3            6.67E-07                                          0.0019                                              LINCO1688 intergenic                               NA
  Chr7:158766826-158767135   3            5.24E-06                                          0.0129                                              WDR60 intergenic                                   Island

Both Slk, uncorrected Stouffer-Liptak-Kechris *P* values, and Sidak *P* values corrected for multiple testing are reported.

5′UTR , 5 prime untranslated region; cds, coding sequence; TSS, transcription start site; nc_intron, non-coding intron, nc_exon, non-coding exon.

###### 

characteristics of DMRs

  Genes annotated to DMRs                                     Putative gene function                                                                                                                                                                                                         Related pathways
  ----------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------
  *ATP6V1E1* (ATPase H + transporting V1 subunit E1)          Encodes component of vacuolar ATPase (V-ATPase) that mediates acidification of intracellular compartments in eukaryotic cells necessary for variety of intracellular processes ([@dvz023-B32], [@dvz023-B66], [@dvz023-B67])   Innate immune systemSynaptic vesicle cycle
  *C2* (complement C2)                                        Serum glycoprotein part of pathway of the complement system responsible for regulating immune responses ([@dvz023-B33], [@dvz023-B68])                                                                                         Innate immune systemComplement pathway
  *CTNNA2* (catenin alpha 2)                                  Involved in regulating cell--cell adhesion and differentiation in the nervous system. Essential for proper regulation of cortical neuronal migration and neurite growth ([@dvz023-B34], [@dvz023-B69])                         Blood--brain barrier and immune cell transmigrationSertoli--sertoli cell junction dynamics
  *ACSF3* (acyl-CoA synthetase family member 3)               Catalyzes initial reaction in mitochondrial fatty acid synthesis ([@dvz023-B70])                                                                                                                                               Regulation of lipid metabolism by peroxisome proliferator-activated receptor alpha (PPARalpha)Fatty acid biosynthesis
  *Linc01688* (long intergenic non-protein coding RNA 1688)   Unknown                                                                                                                                                                                                                        
  *WDR60* (Wd repeat domain 60)                               Encodes a member of the WD repeat protein family. Involved in variety of cellular processes including cell cycle progression, signal transduction, apoptosis, and gene regulation ([@dvz023-B71])                              Organelle biogenesis and maintenanceIntraflagellar transport

Differentially Mediated Probe Analysis
--------------------------------------

Epigenome-wide association between father's smoking and offspring DNA methylation at a single probe level identified 33 CpGs that passed epigenome-wide significance at a FDR rate *P* \< 0.05 ([Fig. 1](#dvz023-F1){ref-type="fig"}). However, the EWAS exhibited a genomic inflation factor (lambda) of 1.462 ([Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}). After applying correction for genomic inflation using the BACON method, epigenome-wide association between father's smoking and offspring DNA methylation identified 37 significantly differentially methylated CpG sites (inflation-adjusted *P*-value \<0.0001) ([Supplementary Figs S2 and S3](#sup1){ref-type="supplementary-material"}). After subsequent filtering of data and removal of CpG sites having SNPs within the region of ±50 bp of the CpG, and with minor allele frequency ≥0.05, we retained 32 differentially mediated probes (DMPs) with differential methylation between exposure groups for enrichment analysis ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). The top 10 DMPs are presented in [Table 4](#dvz023-T4){ref-type="table"}. Among these, four were related to innate and adaptive immunity and various immune cell subsets (*BCAS1*, *MFGE8*, *UNC93B1*, and *RALB*) ([@dvz023-B21]). Another DMP (*DLGAP1*) was related to neuronal systems and behavioural disorders ([@dvz023-B25]).

![Manhattan plot for paternal smoking EWAS (before adjusted for genomic inflation). In the plot, the vertical axis indicates (−log10 transformed) observed *P* values, and the horizontal axis indicates chromosome positions with the points indicating individual CpG. Red line: Bonferroni threshold and blue line: Multiple testing correction threshold (FDR \< 0.05)](dvz023f1){#dvz023-F1}

###### 

differentially methylated probe analysis (corrected *P*-value \<0.00001)

  PROBEID      BETA     SE      *P*-value   Adj *P*-value   CHR   MAPINFO       Gene
  ------------ -------- ------- ----------- --------------- ----- ----------- ---------
  cg05019203   −0.018   0.003   2.83E-08    4.40E-06        20    52612962      BCAS1
  cg25727029   0.013    0.002   3.56E-08    5.16E-06        15    89482453      MFGE8
  cg00626693   −0.014   0.003   6.27E-08    7.64E-06        16    30622810     ZNF689
  cg19754387   0.006    0.001   1.33E-07    1.29E-05        2     208576057    CCNYL1
  cg24534854   −0.013   0.003   2.09E-07    1.76E-05        8     22582613      PEBP4
  cg20272935   0.024    0.005   3.02E-07    2.27E-05        11    67765720     UNC93B1
  cg04164584   −0.010   0.002   3.44E-07    2.49E-05        17    27235821      PHF12
  cg06876354   0.017    0.003   4.65E-07    3.07E-05        2     121020189     RALB
  cg25012097   −0.012   0.002   4.74E-07    3.11E-05        13    39263863      FREM2
  cg07217718   0.025    0.005   6.17E-07    3.73E-05        18    3585484      DLGAP1

PROBEID, probe identifiers; BETA, estimates; SE, standard error; Adj *P*-value, *P*-value adjusted by multiple test correction; CHR, chromosome; MAPINFO, position of the CpGs in the chromosome; Gene, UCSC RefGene.

Enrichment Analysis
-------------------

Enrichment analysis of the 32 DMPs ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}) using Enrichr for transcription factor-binding sites identified by the Encyclopedia of DNA elements (ENCODE) and Epigenomic roadmap project did not identify significant enrichment in regulatory regions ([Supplementary Tables S2--S4](#sup1){ref-type="supplementary-material"} and [Figs S4--S6](#sup1){ref-type="supplementary-material"}).

Analyses using ontologies defined in the KEGG (Kyoto Encyclopedia of Genes and Genomes) and GO (Gene Ontology) databases retrieved pathways and terms, and although not statistically significant, results from top 10 KEGG pathways showed enrichment of addiction behaviours (nicotine addiction). Summary statistics of top 10 GO and KEGG enrichment results are shown in [Tables 5](#dvz023-T5){ref-type="table"} and [6](#dvz023-T6){ref-type="table"}, respectively.

###### 

top 10 enriched pathways in GO molecular function, biological processes, and cell compartment identified using genes CpGs (threshold: inflation-adjusted *P*-value \<0.0001)

  **Ontology and term** [^a^](#tblfn8){ref-type="table-fn"}   ID                                                           CpGs in tern  Meth CpGs   *P*-value   
  ----------------------------------------------------------- ----------------------------------------------------------- -------------- ----------- ----------- ---------
  MF                                                          Selenomethionine adenosyltransferase activity                 GO:0098601   1           1           \<0.001
  MF                                                          Methionine adenosyltransferase activity                      GO: 0004478   2           1           0.001
  MF                                                          Extracellularly glutamate-gated chloride channel activity     GO:0008068   1           1           0.002
  BP                                                          Regulation of exocyst assembly                                GO:0001928   1           1           0.002
  BP                                                          Regulation of exocyst localization                            GO:0060178   1           1           0.002
  CC                                                          Excitatory synapse                                            GO:0060076   48          2           0.002
  BP                                                          S-adenosylmethionine biosynthetic process                     GO:0006556   3           1           0.002
  BP                                                          Sequestering of neurotransmitter                              GO:0042137   2           1           0.003
  BP                                                          Synaptic vesicle lumen acidification                          GO:0097401   2           1           0.003

Ontology: BP, biological process; CC, cell compartment; MF, molecular function; ID, GO identifier; CpG in term, number of CpGs in GO term; Meth.CpGs, number of significant CpGs.

###### 

top 10 enriched pathways in KEGG using genes CpGs (threshold: inflation-adjusted *P*-value \<0.0001)

  KEGG   Pathway                                         ID        CpGs in path   Meth. CpGs   *P*-value
  ------ ----------------------------------------- --------------- -------------- ------------ -----------
  KEGG   ECM--receptor interaction                  path:hsa04512  86             2            0.006
  KEGG   Glutamatergic synapse                      path:hsa04724  114            2            0.011
  KEGG   Nicotine addiction                         path:hsa05033  40             1            0.047
  KEGG   Cysteine and methionine metabolism         path:hsa00270  48             1            0.049
  KEGG   Biosynthesis of amino acids                path:hsa01230  74             1            0.063
  KEGG   Synaptic vesicle cycle                     path:hsa04721  78             1            0.093
  KEGG   Pancreatic cancer                          path:hsa05212  75             1            0.095
  KEGG   Colorectal cancer                          path:hsa05210  86             1            0.104
  KEGG   Retrograde endocannabinoid signalling      path:hsa04723  141            1            0.149
  KEGG   Cytokine--cytokine receptor interaction    path:hsa04060  289            1            0.167

Pathway, KEGG pathway; ID, pathway identifier; CpG in path, number of CpGs in pathway; Meth.CpGs, number of significant CpGs.

Sensitivity Analyses
--------------------

To address the issue of relatedness among some of the participants (siblings in RHINESSA, *n* = 44), we performed linear mixed models on the 32 significant (inflation-adjusted *P*-value \<0.0001) CpG sites, where family ID was included as random effect. All 32 CpGs were sustained in these analyses ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}).

To account for potential confounding by social class, we conducted a sensitivity analysis adjusting for paternal socio-economic background by adding education as a proxy for socio-economic status to the regression model. Methylation at all the selected CpG sites (inflation-adjusted *P*-value \<0.0001) was still associated with paternal smoking in this analysis ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}).

Replication Analysis
--------------------

Due to the amount of missing CpG sites between the EPIC and the 450 K microarray, we could not pursue replication of the significant DMRs identified in the DMR analysis. We undertook replication of the selected CpG sites (inflation-adjusted *P*-value \<0.0001) in a subsample from Isle of Wight (IoW) with available data from cord blood DNA samples (*N* = 159, study characteristics presented in [Supplementary Table S7](#sup1){ref-type="supplementary-material"}). However, due to different methylation array platforms, and because some CpGs were discarded by pre-processing, only 13 out of the 32 CpGs identified in the ECRHS/RHINESSA cohort were available for replication in the IoW cohort ([Supplementary Table S7](#sup1){ref-type="supplementary-material"}).

Discussion
==========

In the present study, we have measured epigenome-wide CpG site-specific DNA methylation in adolescent and adult offspring and identified six significant DMRs (Sidak-corrected *P* values 0.0006--0.0173) related to father's smoking. To our knowledge, this is the first study suggesting persisting effects of paternal smoking on offspring DNA methylation. Although previous genome-wide associations of maternal smoking suggest that associations with DNA methylation changes in offspring tend to weaken with increasing age of the offspring ([@dvz023-B26]), and our study subjects will have accumulated a range of exposures influencing DNA methylation, it is remarkable that we were able to detect methylation differences associated with paternal smoking in persons aged 11--54 years.

Of the six statistically significant DMRs identified, one region overlapped with intron 11 within the catenin alpha-2 (*CTNNA2*) gene. *CTNNA2* has previously been shown to be differentially methylated in relation to smoking ([@dvz023-B18], [@dvz023-B27], [@dvz023-B28]). It is expressed across the central nervous system and suggested involved in behavioural dysfunction and addiction ([@dvz023-B29]). Although it did not harbour a CpG island, which would have provided additional support for a regulatory role for this region, DNA methylation at intronic sequences outside CpG islands may also be of functional important ([@dvz023-B30]). Two DMRs (*ATP6V1E* and *WDR60*), co-localized with CpG islands, and the region within ATP6V1E1 covered parts of the 5 prime untranslated region (5′UTR) and the coding sequence of the gene. One DMR, annotated to the *C2* gene on chromosome 6, was located to a CpG island shore (regions within 2000 bp of a CpG island), and overlapped with the transcription start site (TSS) as well as the 5′UTR and exon 1 of *C2*. Although this indicates regulatory functions of the DMRs, they consist of CpGs of only nominal significance and differential methylation could reflect irregular spacing of probes and should be interpreted with caution as they may introduce false-positive results.

When exploring the biological impact of annotated genes, there were similar patterns in the DMR and DMP analyses, although the identified DMPs did not remain significant at epigenome-wide levels of significance. Two of the significant DMRs (*ATP6V1E1* and *C2*) and four of the top DMPs (*BCAS1*, *MFGE8*, *UNC93B1*, and *RALB*) were annotated to genes related to innate and adaptive immunity and to different immune cell subsets ([@dvz023-B21], [@dvz023-B31], [@dvz023-B32]). Furthermore, one DMR (*CTNNA2*) and one DMP (*DLGAP1*) mapped to genes involved in function and development of neuronal systems ([@dvz023-B25], [@dvz023-B33]), and to behavioural dysfunction ([@dvz023-B29], [@dvz023-B34], [@dvz023-B35]).

Except *CTNNA2* ([@dvz023-B18]), none of our significant DMRs or top DMPs are previously reported in epigenome-wide studies of the effect of maternal smoking ([@dvz023-B16], [@dvz023-B17], [@dvz023-B36]), or current or lifetime personal smoking exposure ([@dvz023-B12], [@dvz023-B40]). This is also in agreement with Joubert *et al.* who demonstrated that the CpGs differentially methylated in relation to maternal smoking were not associated with paternal smoking ([@dvz023-B43]). Given the differences in gamete development in males and females, it seems biologically plausible that exposure effects through the maternal and paternal line may differ and induce epigenetic modifications at different loci. Further, it seems plausible that effects transmitted across generations may differ from those of personal smoking. To investigate whether the DMP-specific DNA methylation differences were driven by relatedness among participants, we conducted a sensitivity analysis accounting for family. All the top DMPs remained suggesting that our findings were not due to residual confounding by genetic or family-related environmental factors.

There is increasing evidence of shared pathophysiology between nicotine dependence and neuropsychiatric disorders ([@dvz023-B44]), and smoking has been reported to modify genes that predispose to addictive behaviours ([@dvz023-B27], [@dvz023-B45]). In previous literature, maternal smoking during pregnancy has been associated with adverse neurodevelopmental outcome ([@dvz023-B46]) and behavioural alterations in offspring ([@dvz023-B20], [@dvz023-B47]). Enrichment analysis of the top 32 differentially methylated probes (adj. *P* \< 0.00001) identified GO terms and KEGG pathways involved in developmental and regulatory processes of the brain and the central nervous system and nicotine addiction, suggesting that paternal smoking may also induce aberrant methylation in genes related to neurodevelopment. However, as the identified CpGs did not remain significant epigenome-wide after adjustment for inflation, results from the KEGG and GO enrichment analysis should be interpreted with caution and may not be valid.

When we explored the biological and regulatory role of differentially methylated loci by investigating ENCODE and Epigenomic roadmaps annotated regulatory domains, we found no significant enrichment for histone modification signatures and transcription factor sites among our significant CpG sites. Whether the detected methylation differences can introduce functional changes at the gene transcriptional level needs further investigation.

The present study cannot differentiate whether the observed association of father's smoking with offspring DNA methylation may be due to second-hand smoke exposure during the gestational period and/or childhood (post-conception) or due to altered sperm DNA methylation patterns transmitted to the offspring (pre-conception). A pre-conception effect is suggested by previous studies showing that the strongest effect of father's smoking on offspring phenotype was observed when smoking occurred before conception and particularly at an early age ([@dvz023-B7], [@dvz023-B8], [@dvz023-B48]). However, further studies with detailed information about exposure onset in large samples will be required to address this.

The identified DMPs associated with father's smoking showed relatively small effect estimates, with top 10 CpG beta values relative to offspring of smoking and non-smoking fathers ranging from −0.02 to 0.03. This is in line with previous findings where DNA methylation differences associated with environmental exposures are characterized by small changes on the scale of 2--10% ([@dvz023-B30], [@dvz023-B49]). However, previous studies have demonstrated that even small changes can impact transcriptional activity and be consistent in different populations and across age groups ([@dvz023-B17], [@dvz023-B49]). Although associations with *in utero* maternal smoking have shown higher estimates, ranging from −0.28 to 0.18 ([@dvz023-B16], [@dvz023-B18], [@dvz023-B26]), we would expect DNA methylation changes related to paternal exposures to be subtler when compared to direct effects from placenta--foetus interactions. Further, smaller effect estimates could be expected considering that we analyzed associations of father's smoking with DNA methylation in adolescents and adults. The fact that we found epigenomic regions (DMRs) associated with paternal smoking, adds functional relevance to our discoveries, as it implies differential methylation in regions that may affect regulation of transcription. These regional changes are also more robust as they are less prone to SNP effects and risk of false-positive findings as compared to site-by-site analysis, and they improve the specificity and potentially functional relevance of our findings ([@dvz023-B50]).

A main limitation of our study is the relatively small study population. The present study was underpowered to allow stratification by offspring's sex or age, hence we did not address potential variability of effect estimated by gender or in different age groups. On the other hand, the study participants come from population-based cohorts, which is a strength of the study and to some degree allows for generalization of the results. In thorough analyses, we have accounted appropriately for the study design with two linked cohorts and family members. Further, we had information on personal smoking as well as smoking in both parents and have been able to account for main confounding factors (potentially associated with both the exposure and the outcome) in the analyses. However, rest confounding from included and unknown factors may still be present.

We have not been able to verify our findings in an independent cohort. We pursued replication in a sample from the IoW third-generation study, however, replication of significant DMRs proved not be possible as different methylation platforms were used in the two cohorts (Illumina 450K in IoW and Illumina EPIC Beadchip in RHINESSA/ECRHS) and a large number of sites were missing in the replication analysis. Few other cohorts have reliable and extensive information on father's smoking, while personal or maternal smoking are often well documented. Thus, the novel findings of DMRs related to father's tobacco smoking in our analyses, should be considered hypothesis generating and be interpreted with caution.

Conclusion
==========

In conclusion, this hypothesis generating EWAS study is the first to report associations between paternal smoking and DNA methylation characteristics in adult and adolescent offspring. It is notable that differential methylation was detectable in this age group. Our results are intriguing as they indicate that fathers' exposures might persistently modify their future offspring's epigenome. This emphasizes the necessity to focus on male-line exposures in relation to phenotypic variation in their children, and further research to replicate our findings and explore potential mechanisms.

Methods
=======

Study Population
----------------

This study included data from 195 males and females aged 11--54 years participating in two linked population-based cohorts ([Fig. 2](#dvz023-F2){ref-type="fig"}).

![flowchart of study population. Offspring originate from two linked study populations with standardized and harmonized protocols: the ECRHS and the RHINESSA](dvz023f2){#dvz023-F2}

The ECRHS conducted a study of population-based random samples of adult women and men aged 20--44 years in 1990--94 and followed up participants with clinical investigations in 2002--04 and 2012--14. The present analysis included 100 participants from the Bergen study centre with available DNA methylation data from DNA collected in ECRHS II. Information on father's year of birth was obtained from the Norwegian National Registry.

The Respiratory Health in Northern Europe, Spain and Australia study (RHINESSA) ([www.rhinessa.net](http://www.rhinessa.net)) investigated the offspring of ECRHS study participants in 10 study centres, following standardized protocols harmonized with the ECRHS protocols. The present analysis included 95 participants from the Bergen study centre in which DNA methylation was measured.

For the present analysis, offspring from the two cohorts were merged and analysed together. Information on smoking and other variables were obtained through interviews. Unless otherwise stated, definitions are similar in the two cohorts.

The study was approved by the Regional Committee for Medical and Health Research Ethics in Western Norway (RHINESSA: 2012/2017; ECRHS: 2010/759), and each participant gave written informed consent prior to participation.

Smoking Exposure and Covariates
-------------------------------

In the RHINESSA cohort, information on fathers' smoking habits was collected from longitudinal data given by the fathers themselves as participants in the ECRHS II study, responding to the question: (i) *Have you ever smoked for as long as a year?*. In the ECRHS cohort, information on father's smoking was reported by the ECRHS participants and based on the question: *Did your father ever smoke regularly during your childhood?* Father's smoking was categorized as a binary variable, as having smoked or not during offspring's childhood. In the present analysis paternal smoking was not defined in more detail as information regarding age of smoking onset was only available for RHINESSA participants.

Information on mothers smoking was reported by participants based on the question: *Did your mother ever smoke regularly during your childhood*, *or while pregnant with you?* *with the answering* categories 'no' (*n* = 128), 'yes' (*n* = 62), or 'don't know' (*n* = 5) Maternal smoking was dichotomized as either having smoked ('yes') or never smoked ('no') during offspring's childhood, whereas 'don't' know' replies were excluded from further analyses.

Personal smoking was classified as current, ex or never smoking, based on the questions: i. *Have you ever smoked for as long as a year?* (ii) *If yes* *How old were you when you started smoking?* (iii) *Have you stopped or cut down smoking?* (iv) *How old were you when you stopped or cut down smoking?* Number of pack years was calculated based on the number of years smoked and the average number of daily cigarettes.

Parental educational attainment was categorized in as lower (primary school), intermediate (secondary school) and higher education (college or university). Personal education level was defined the same way in RHINESSA and categorized in three levels based on reported age when education was completed in ECRHS.

Methylation Measurements and Quality Control
--------------------------------------------

DNA was extracted from whole blood using a standard salting out procedure ([@dvz023-B51]). Samples were processed with the Illumina MethylationEPIC Beadchip microarray, which assesses methylation at \> 850 000 CpGs. Methylation measurements were performed by the Oxford Genomics Centre (Oxford, UK) using the EZ 96-DNA methylation kit (Zymo Research, CA, USA), following the manufacturer's standard protocol, with multiple identical control samples assigned to each bisulphite conversion batch to assess assay variability. Samples were randomly distributed on microarrays to control against batch effects. The CPACOR pipeline ([@dvz023-B52]) was used to pre-process and normalize the methylation data. We removed probes with CpG loci located on sex chromosomes and probes located at 0 distance to known SNPs. We applied Illumina background correction to all intensity values. Any intensity values having detection *P* values \>=10^−16^ were set as missing data. Samples with call rate \<98% were excluded. After pre-processing, 765 082 sites remained for subsequent analysis. A quantile normalization was applied using limma on intensity values separately based on six different probe-type categories (Type-I M red, Type-I U red, Type-I M green, Type-I U green, Type-II red, and Type-II green). Beta values were then calculated from these normalized intensity values. ComBat was used to correct for batch effects ([@dvz023-B53]).

Statistical Analyses
--------------------

For identification of DMRs, composed of multiple signals across individual CpG positions, we used Comb-p ([@dvz023-B54]) (Python version 2.7). This method identifies regions enriched for low *P* values based on the probe location and unadjusted *P* values from the site-specific CpG analysis. For each region the comb-p algorithm adjusts the CpG *P* values for auto-correction between probes by using the Stouffer-Liptak-Kechris (slk) correction, followed by multiple testing adjustment using a one-step Sidak correction method ([@dvz023-B54]). Regions containing at least two probes and having a Sidak-corrected *P*-value \<0.05 were considered statistically significant.

Robust multivariate linear regression models were used to analyse the association of offspring differentially associated probes (DMPs) adjusted for paternal and offspring age, offspring gender, as well as personal and maternal smoking status. Educational level was added in sensitivity analyses to account for socio-economic status. Cell proportions (CD8T, CD4T, NK, B Cells, Monocytes, Granulocytes) were estimated using the minfi package ([@dvz023-B55]) (R version 3.4.2), and cell composition coefficients were derived using the Houseman method ([@dvz023-B56]). These were additively included in the model. Multiple hypothesis testing was accounted for by controlling the false discovery rate (FDR), using Benjamini and Hochberg's algorithm ([@dvz023-B57]). CpGs with FDR-corrected *P*-value \<0.1 were considered statistically significant and normalized methylation betas were used as outcome measurements. In order to address possible inflation of our test statistics by systematic biases, a Bayesian method based on estimation of the empirical null distribution was applied using the R/Bioconductor package BACON ([@dvz023-B58]), and *P* values were estimated.

Some of the study participants originated from the same family. To account for this, we performed linear mixed model analysis on the top CpGs including family IDs as random effect.

For CpG annotation, we used the UCSC Genome browser annotation provided by Illumina in the array manifest together with SNIPPER (version 1.2, <http://csg.sph.umich.edu/boehnke/snipper/>) to annotate the nearest gene within 10 Mb of each CpG.

To investigate the regulatory context of the top differentially methylated probes (inflation-adjusted *P*-value \<0.00001), we performed enrichment analysis in annotated regulatory elements (TF Chip seq and histone modification signatures) from the ENCODE ([@dvz023-B59]), as well as the Epigenomics roadmap ([@dvz023-B60]) using Enrichr ([@dvz023-B61]).

Pathway analysis was conducted using KEGG ([@dvz023-B62]), and GO databases ([@dvz023-B63]) using gometh function in the missMethyl package ([@dvz023-B52]).

Replication in Isle of Wight Cohort
-----------------------------------

To pursue replication of findings, we used the IoW third-generation study which since 2010 has enrolled children born to second-generation parents---the original Birth cohort. Extensive descriptions of the IoW multigenerational cohort design and objectives have been published elsewhere ([@dvz023-B64], [@dvz023-B65]). Father's smoking information given by the fathers themselves, and DNA methylation measurements using the Illumina Infinium HumanMethylation450 Beadchip array in cord blood DNA available for 159 subjects were included in the present analysis.
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